Vifor (international) Ag

Vifor Ag

Susan Boyce

Wilm Buhr

Christopher John Yarnold

Susanna Burckhardt

Franz Dürrenberger

Cristina Lecci

Stefan Reim

Michael Burgert

John Scott

Aris Kalogerakis

Jon Shepherd

Vania Manolova

Richard Jarjes-Pike

Paula Pena

Stephen Martin Courtney

Peter Geisser

Felix Funk

Vincent A Corden

Graham Dawson

Tara Davenport

Mark Slack

Mark P Ridgill

Albertus A Ellenbroek

Mark Peter Ridgill

Peter Otto Geisser

Vincent Anthony Corden

Albertus Antonius Ellenbroek

The invention relates to novel compounds of the general formula (I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.

Ferroportin inhibitors

The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis. 

The invention relates to novel compounds of the general formula (A-I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula (AA) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis. 

The present invention relates to novel hepcidin antagonists, pharmaceutical compositions comprising them and the use thereof as medicaments for the use in the treatment of iron metabolism disorders, such as, in particular, iron deficiency diseases and anemias, in particular anemias in connection with chronic inflammatory diseases.

Sulfonaminoquinoline hepcidin antagonists

Growing community of inventors

Quickborn, Germany

Susan Boyce